{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:27:51Z","timestamp":1789194471720,"version":"build-2803163510"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s11307-021-01600-5","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T19:04:42Z","timestamp":1617822282000},"page":"766-774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of 68Ga DOTATOC as Assessed by Dynamic Whole-body PET in Patients with Neuroendocrine Tumors: Implications for Diagnosis and Therapy"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0922-6519","authenticated-orcid":false,"given":"Martin A.","family":"Lodge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilja B.","family":"Solnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad A.","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"key":"1600_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","volume":"9","author":"IM Modlin","year":"2008","unstructured":"Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP, Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin A (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9:61\u201372","journal-title":"Lancet Oncol"},{"key":"1600_CR2","first-page":"1825","volume":"36","author":"JC Reubi","year":"1995","unstructured":"Reubi JC (1995) Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med. 36:1825\u20131835","journal-title":"J Nucl Med."},{"issue":"7","key":"1600_CR3","doi-asserted-by":"publisher","first-page":"e19162","DOI":"10.1097\/MD.0000000000019162","volume":"99","author":"A Tolomeo","year":"2020","unstructured":"Tolomeo A, Lopopolo G, Dimiccoli V, Perioli L, Modoni S, Scilimati A (2020) Impact of 68Ga-DOTATOC PET\/CT in comparison to 111In-Octreotide SPECT\/CT in management of neuro-endocrine tumors: a case report. Medicine. 99(7):e19162","journal-title":"Medicine."},{"key":"1600_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.2967\/jnumed.106.035667","volume":"48","author":"M Gabriel","year":"2007","unstructured":"Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, Kovacs P, von Guggenberg E, Bale R, Virgolini IJ (2007) 68Ga-DOTA-tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 48:508\u2013518","journal-title":"J Nucl Med."},{"issue":"Suppl 1","key":"1600_CR5","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1007\/s00259-011-2039-y","volume":"39","author":"BL Kam","year":"2012","unstructured":"Kam BL, Teunissen JJ, Krenning EP et al (2012) Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 39(Suppl 1):S103\u2013S112","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"1600_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2967\/jnumed.119.238287","volume":"61","author":"JJ Sunderland","year":"2020","unstructured":"Sunderland JJ (2020) The academic NDA: justification, process, and lessons learned. J Nucl Med. 61:480\u2013487","journal-title":"J Nucl Med."},{"key":"1600_CR7","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.2967\/jnumed.111.091165","volume":"52","author":"TD Poeppel","year":"2011","unstructured":"Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C (2011) 68Ga-DOTATOC versus 68Ga-DOTATATE PET\/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 52:1864\u20131870","journal-title":"J Nucl Med."},{"key":"1600_CR8","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2967\/jnumed.113.126177","volume":"55","author":"I Velikyan","year":"2014","unstructured":"Velikyan I, Sundin A, Sorensen J, Lubberink M, Sandstrom M, Garske-Roman U, Lundqvist H, Granberg D, Eriksson B (2014) Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification. J Nucl Med. 55:204\u2013210","journal-title":"J Nucl Med."},{"key":"1600_CR9","unstructured":"FDA Approves Detectnet. Drugs.com. September 8, 2020. Available at: https:\/\/www.drugs.com\/newdrugs\/fda-approves-detectnet-copper-cu-64-dotatate-positron-emission-tomography-pet-agent-5347.html. Accessed 27 Jan 2021."},{"key":"1600_CR10","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1007\/s00259-010-1512-3","volume":"37","author":"I Virgolini","year":"2010","unstructured":"Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, Papathanasiou ND, Pepe G, Oyen W, de Cristoforo C, Chiti A (2010) Procedure guidelines for PET\/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 37:2004\u20132010","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"1600_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.nucmedbio.2009.11.008","volume":"37","author":"I Velikyan","year":"2010","unstructured":"Velikyan I, Sundin A, Eriksson B, Lundqvist H, S\u00f6rensen J, Bergstr\u00f6m M, L\u00e5ngstr\u00f6m B (2010) In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours \u2014 impact of peptide mass. Nucl Med Biol. 37:265\u2013275","journal-title":"Nucl Med Biol."},{"key":"1600_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"JJ Zaknun","year":"2013","unstructured":"Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, H\u00f6rsch D, O\u2019Dorisio MS, O\u2019Dorisiol TM, Howe JR, Cremonesi M, Kwekkeboom DJ (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 40:800\u2013816","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"1600_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2967\/jnumed.110.079004","volume":"52","author":"H Zhang","year":"2011","unstructured":"Zhang H, Moroz MA, Serganova I, Ku T, Huang R, Vider J, Maecke HR, Larson SM, Blasberg R, Smith-Jones PM (2011) Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68Ga-DOTATOC. J Nucl Med. 52:123\u2013131","journal-title":"J Nucl Med."},{"key":"1600_CR14","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1007\/s00259-017-3728-y","volume":"44","author":"FM Bozkurt","year":"2017","unstructured":"Bozkurt FM, Virgolini I, Balogova S et al (2017) Guideline for PET\/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F\u2013DOPA. Eur J Nucl Med Mol Imaging. 44:1588\u20131601","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"1600_CR15","first-page":"1960","volume":"47","author":"BJ Kemp","year":"2006","unstructured":"Kemp BJ, Kim C, Williams JJ, Ganin A, Lowe VJ (2006) NEMA NU 2-2001 performance measurements of an LYSO-based PET\/CT system in 2D and 3D acquisition modes. J Nucl Med. 47:1960\u20131967","journal-title":"J Nucl Med."},{"key":"1600_CR16","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1097\/MNM.0b013e3282f1753d","volume":"28","author":"C Decristoforo","year":"2007","unstructured":"Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A, Virgolini I, Haubner R (2007) A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun. 28:870\u2013875","journal-title":"Nucl Med Commun."},{"key":"1600_CR17","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00259-018-4153-6","volume":"46","author":"A Rahmim","year":"2019","unstructured":"Rahmim A, Lodge MA, Karakatsanis NA, Panin VY, Zhou Y, McMillan A, Cho S, Zaidi H, Casey ME, Wahl RL (2019) Dynamic whole-body PET imaging: principles, potentials and applications. Eur J Nucl Med Mol Iaging. 46:501\u2013518","journal-title":"Eur J Nucl Med Mol Iaging."},{"key":"1600_CR18","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.2967\/jnumed.111.089276","volume":"52","author":"AR Haug","year":"2011","unstructured":"Haug AR, Rominger A, Mustafa M, Auernhammer C, Goke B, Schmidt GP, Wangler B, Cumming P, Bartenstein P, Hacker M (2011) Treatment with octreotide does not reduce tumor uptake of 68Ga-DOTATATE as measured by PET\/CT in patients with neuroendocrine tumors. J Nucl Med. 52:1679\u20131683","journal-title":"J Nucl Med."},{"key":"1600_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2967\/jnumed.117.192203","volume":"59","author":"N Ayati","year":"2018","unstructured":"Ayati N, Lee ST, Zakavi R, Pathmaraj K, al-Qatawna L, Poon A, Scott AM (2018) Long-acting somatostatin analog therapy differentially alters 68Ga-DOTATATE uptake in normal tissues compared with primary tumors and metastatic lesions. J Nucl Med. 59:223\u2013227","journal-title":"J Nucl Med."},{"key":"1600_CR20","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.2967\/jnumed.119.226332","volume":"60","author":"A Galne","year":"2019","unstructured":"Galne A, Almquist H, Almquist M et al (2019) A prospective observational study to evaluate the effects of long-acting somatostatin analogs on 68Ga-DOTATATE uptake in patients with neuroendocrine tumors. J Nucl Med. 60:1717\u20131723","journal-title":"J Nucl Med."},{"key":"1600_CR21","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s00259-018-4117-x","volume":"46","author":"EA Aalbersberg","year":"2019","unstructured":"Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MW et al (2019) Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation. Eur J Nucl Med Mol Imaging 46:696\u2013703","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1600_CR22","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/BF00209003","volume":"20","author":"U Dorr","year":"1993","unstructured":"Dorr U, Rath U, Sautter-Bihl M et al (1993) Improved visualisation of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue. Eur J Nucl Med. 20:431\u2013433","journal-title":"Eur J Nucl Med."},{"key":"1600_CR23","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/2191-219X-3-82","volume":"3","author":"A Sabet","year":"2013","unstructured":"Sabet A, Nagarajah J, Dogan AS, Biersack HJ, Sabet A, Guhlke S, Ezziddin S (2013) Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions? EJNMMI Res. 3:82","journal-title":"EJNMMI Res."}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01600-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-021-01600-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-021-01600-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T15:29:35Z","timestamp":1630510175000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-021-01600-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1600"],"URL":"https:\/\/doi.org\/10.1007\/s11307-021-01600-5","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"1 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"The authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}